Summary
The pharmacokinetics of fluconazole given orally (100mg) or intraperitoneally (50 and 150mg) were determined in 15 patients with chronic renal failure who were undergoing continuous ambulatory peritoneal dialysis. The half-life (72 to 85 hours) was intermediate between values obtained in healthy volunteers and in patients with renal insufficiency studied during an interhaemodialysis period. The peritoneal clearance, 0.26 to 0.33 L/h, led to an 18% recovery of administered drug in the dialysates after 48 hours. The peritoneal absorption was slow (time to peak plasma concentration 7 hours) but the peritoneal bioavailabilily was excellent at 87 ± 5%. The mean concentrations of fluconazole up to 24 hours were 770 and 1900 μg/L after single intraperitoneal doses of 50 and 150mg, respectively. The volume of distribution (40 to 60L) did not differ from that determined in patients with normal renal function. In the case of fungal peritonitis essentially attributed to Candida spp., a 6-hour intraperitoneal infusion of fluconazole 150mg every 2 days appears to be a good regimen to rapidly exceed minimum inhibitory concentrations and treat infection without risk of systemic dissemination of fungi or toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brammer KW, Tarbit MH, A review of the pharmacokinetics of fluconazole (UK-49.858) in laboratory animals and man. In Fromthng (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents, pp. 141–149, J.R. Prous Science Publishers, Barcelona, 1987
Debruyne D, Ryckelynck JPh, Bigot MC, Moulin M. Determinalion of fluconazole in biological fluids by capillary column gas chromaiography with a nitrogen detector. Journal of Pharmaceutical Sciences 77: 534–535, 1988
Debruync D, Ryckelynck JPh, Hurault de Ligny B, Moulin M. Pharmacokinctics of piperacillin in patients on peritoneal dialysis with and without peritonitis. Journal of Pharmaceutical Sciences, 79: 99–102, 1990
Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Reviews of Infectious Diseases 8: 309–321, 1986
Cibaldi M, Perrier D, Pharmacokinetics. Marcel Dekker, New York, 1975
Henderson JT, Fluconazole — a significant advance in the management of human fungal disease. In Fromtling (Ed.) Recent trends in the discovery, development and evaluation of anti-fungal agents, pp. 77–79, J.R. Prous Science Publishers, Barcelona, 1987
Hugues CE, Beggs WH. Action of fluconazole (UK-49.858) in relation to other systemic antifungal azoles. Journal of Anlirnicrobial Chemotherapy 19: 171–174, 1987
Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinelic evaluation of UK-49.858. a mclabolically stable lriazolc antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 28: 648–653, 1985
Marriol MS, Richardson K. The discovery and mode of action of fluconazole. In Fromtling (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents, pp. 81–92, J.R. Prous Science Publishers. Barcelona, 1987
Meunier F, Gerain J, Snock R, Libotte F, Lamber C. Fluconazole therapy of oropharyngal candidiasis in cancer patients. In Fromlling (Ed.) Recent trends in the discovery, development and evaluation of antifungal agents, pp. 169–174, J.R. Prous Science Publishers, Barcelona, 1987
Odds FC, Cheesman SL, Abbot AB. Antifungal effects of fluconazole, a new triazole antifungal, in vitro. Journal of Antimicrobial chemotherapy 18: 473–478, 1986
Paton TW, Cornish WR, Arifie Manuel M, Hardy BG. Drug therapy in patients undergoing peritoneal dialysis. Clinical Pharmacokinetics 10: 404–426, 1985
Perfect JR, Durack DT. Penetration of imidazolcs and tnazoles into cerebrospinal fluid of rabbits. Journal of antimicrobial chemotherapy 16: 81–86, 1985
Saag M, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrobial Agents and Chemotherapy 32: 1–8, 1988
Savani DV, Perfect JR, Cobo M, Durack DT. Penetration of new azoic compounds into the eye and efficacy in experimental Candida cndophtalmilis. Antimicrobial Agents and Chemotherapy 31: 6–10, 1987
Spach MO, Bromet M. Pharmacocinctiquc du fluconazole chez l’insuffisant rénal chronique. Réunion Interdisciplinaire de Chimiothérapie Infectieuse. Paris, 1988
Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryplococcosis in patients with acquired immunodeficiency syndrome. American Journal of Medicine 85: 481–489, 1988
Toon S, Ross CE, Gokal R, Rowland M. Effects of impaired renal function on the oral pharmacokinelics of fluconazole. X Congress of the International Society for Human and Animal Mycology, Barcelona, 1988
Tucker RM, Williams PL, Arathoon EG, Lcvine BE, Hartstein AI, et al. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrobial Agents and Chemotherapy 32: 369–373, 1988
Van’t Wout JW, Mallie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49, 858) against deep-seated fungal infections. Journal of Antimicrobial Chemotherapy 21: 665–672, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Debruyne, D., Ryckelynck, JP., Moulin, M. et al. Pharmacokinetics of Fluconazole in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Clin Pharmacokinet 18, 491–498 (1990). https://doi.org/10.2165/00003088-199018060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199018060-00006